MicroRNA-155-5p, Reduced by Curcumin-Re-Expressed Hypermethylated BRCA1, Is a Molecular Biomarker for Cancer Risk in BRCA1-methylation Carriers
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24109021 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Nisreen Al-Moghrabi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Epigenetics Section, Department of Molecular Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh 11211, Saudi Arabia. Hauptthemen laut MEDLINE: Curcumin, Carcinoma, Hepatocellular, Liver Neoplasms, MicroRNAs. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This project was funded by the King Faisal Specialist Hospital and Research Centre, King Faisal Specialist Hospital and Research Centre.
Abstract (Originalsprache)
Constitutional BRCA1-methylation is a cancer risk factor for breast (BC) and ovarian (OC) cancer. MiR-155, regulated by BRCA1, is a multifunctional microRNA that plays a crucial role in the immune system. The present study assessed the modulation of miR-155-5p expression in peripheral white blood cells (WBCs) of BC and OC patients and cancer-free (CF) BRCA1-methylation female carriers. Additionally, we investigated the potential of curcumin to suppress miR-155-5p in BRCA1-deficient breast cancer cell lines. MiR-155-5p expression was measured using a stem-loop RT-qPCR method. Gene expression levels were determined using qRT-PCR and immunoblotting. MiR-155-5p was more highly expressed in the BRCA1-hypermethylated HCC-38 and UACC-3199 BC cell lines than in the BRCA1-mutated (HCC-1937) and WT BRCA1 (MDA-MB-321) cell lines. Curcumin suppressed miR-155-5p in the HCC-38 cells but not in the HCC-1937 cells via the re-expression of BRCA1. Elevated levels of miR-155-5p were detected in patients with non-aggressive and localized breast tumors and in patients with late-stage aggressive ovarian tumors, as well as in CF BRCA1-methylation carriers. Notably, IL2RG levels were reduced in the OC and CF groups but not in the BC group. Together, our findings suggest opposing effects of WBC miR-155-5p, according to the cell and cancer type. In addition, the results point to miR-155-5p as a candidate biomarker of cancer risk among CF-BRCA1-methylation carriers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Epigenetics Section, Department of Molecular Oncology, King Faisal Specialist Hospital and Research Centre, Riyadh 11211, Saudi Arabia.
- Department of Life Sciences, College of Science & General Studies, Al Faisal University, Riyadh 11533, Saudi Arabia.
Förderung
- This project was funded by the King Faisal Specialist Hospital and Research Centre
- King Faisal Specialist Hospital and Research Centre
Zitieren
APA
Al-Moghrabi, N., Al-Showimi, M., Al-Yousef, N., & AlOtai, L. (2023). MicroRNA-155-5p, Reduced by Curcumin-Re-Expressed Hypermethylated BRCA1, Is a Molecular Biomarker for Cancer Risk in BRCA1-methylation Carriers. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24109021
Vancouver
Al-Moghrabi N, Al-Showimi M, Al-Yousef N, AlOtai L. MicroRNA-155-5p, Reduced by Curcumin-Re-Expressed Hypermethylated BRCA1, Is a Molecular Biomarker for Cancer Risk in BRCA1-methylation Carriers. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24109021
BibTeX
@article{AlMoghrabi2023,
author = {Al-Moghrabi, Nisreen and Al-Showimi, Maram and Al-Yousef, Nujoud and AlOtai, Lamya},
title = {MicroRNA-155-5p, Reduced by Curcumin-Re-Expressed Hypermethylated BRCA1, Is a Molecular Biomarker for Cancer Risk in BRCA1-methylation Carriers},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24109021}
}
EUVIMED